Following a construction period of just two years, a joint venture between Evonik and the Dutch company DSM has commissioned its globally unique production plant in the US. Through the fermentative manufacture of natural marine algae, the new plant produces a special algal oil that contains the key omega-3 fatty acids needed for healthy salmon farming.
The two parent companies of the 50:50 joint venture named Veramaris, have invested a total of 200 million US dollars in equal parts for the construction of the plant in Blair, Nebraska. The initial algal oil produced at the plant can sustainably supply approximately 15 percent of the annual demand the global salmon-farming industry has for the two omega-3 fatty acids EPA and DHA. The unique process developed by Evonik and DSM enables the manufacture of EPA and DHA for salmon feed for the first time without using any fish oil from wild-caught fish.
“In Veramaris, we have combined the competencies of two strong partners to make an innovative contribution to the healthy nutrition of the world’s growing population, without putting any further burden on our oceans,” says Christian Kullmann, chairman of the Executive Board of Evonik.
Feike Sijbesma, CEO/Chairman DSM Managing Board commented: “I am pleased that together with Evonik we have reached a key milestone in turning the tide: through Veramaris, we are able to reduce the aquaculture industry’s reliance on the world’s finite fish oil resources for these vital omega-3 fatty acids.”
This investment also sees Evonik address one of the Group’s four strategic growth engines: Animal Nutrition. Apart from Animal Nutrition, the Group focuses its investments on Smart Materials, Specialty Additives, and Health & Care.
With Veramaris the Animal Nutrition business line has taken a significant step towards becoming an integrated and innovative system supplier of healthy and sustainable animal nutrition. The joint venture not only complements the portfolio of the business line; together with the business line’s activities in the precision livestock farming sector, it forms one of the most important pillars in the further development of Animal Nutrition.
Every year, 16 million metric tons of wild fish are caught to be used in the manufacture of fish meal and fish oil, which are then used as components in aquaculture feed. Through the addition of amino acids from Evonik and modern feeding concepts, the animal nutrition industry has already managed to significantly reduce the amount of fish meal used in fish feed. Now, the algal oil produced by Veramaris enables the reduction of the fish oil share without impacting the omega-3 fatty acid-content in the farmed fish.
This means that the Veramaris algal oil not only contributes to sustainable aquaculture but also supports healthy human nutrition. The omega-3 fatty acids EPA and DHA are essential fatty acids, contributing to brain, heart and eye health, which humans can only obtain via their food.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.
Evonik’s international activities are organized into six regions. The Asia Pacific North region is headquartered in Shanghai. Sales from continuing operations in Asia Pacific North reached €1.97 billion in 2018. Evonik regards China as one of the driving forces of the global economy and we consequently endeavor to grow our business here. The company now employs over 2,500 employees and has in total of 10 production sites in China.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.